Vera Therapeutics, Inc. $VERA Stock Position Reduced by Rock Springs Capital Management LP

Rock Springs Capital Management LP decreased its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 11.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 503,585 shares of the company’s stock after selling 64,994 shares during the quarter. Vera Therapeutics accounts for approximately 1.2% of Rock Springs Capital Management LP’s holdings, making the stock its 26th largest position. Rock Springs Capital Management LP’s holdings in Vera Therapeutics were worth $20,259,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in VERA. GAMMA Investing LLC raised its position in shares of Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after acquiring an additional 236 shares in the last quarter. Optimize Financial Inc lifted its stake in Vera Therapeutics by 1.5% during the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock worth $901,000 after purchasing an additional 256 shares during the last quarter. Virtus Investment Advisers LLC boosted its holdings in Vera Therapeutics by 5.7% in the fourth quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock worth $271,000 after purchasing an additional 290 shares during the period. Intech Investment Management LLC boosted its holdings in Vera Therapeutics by 2.4% in the fourth quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock worth $903,000 after purchasing an additional 424 shares during the period. Finally, Invesco Ltd. increased its stake in Vera Therapeutics by 2.0% during the second quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock valued at $656,000 after purchasing an additional 550 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

VERA has been the topic of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a report on Friday, July 17th. Guggenheim boosted their price objective on shares of Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. William Blair reissued an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. HC Wainwright upped their target price on Vera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Finally, TD Cowen increased their price target on Vera Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Eleven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $84.58.

Vera Therapeutics Stock Performance

Shares of VERA opened at $35.18 on Tuesday. The firm’s 50 day moving average is $37.02 and its 200-day moving average is $40.01. The stock has a market capitalization of $2.53 billion, a P/E ratio of -6.35 and a beta of 0.92. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. Vera Therapeutics, Inc. has a 12-month low of $19.07 and a 12-month high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter last year, the business earned ($0.81) EPS. Equities research analysts anticipate that Vera Therapeutics, Inc. will post -6.37 EPS for the current fiscal year.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total value of $1,956,375.00. Following the transaction, the chief executive officer owned 151,994 shares in the company, valued at approximately $6,429,346.20. The trade was a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 83,250 shares of company stock valued at $3,337,770 in the last quarter. Insiders own 15.90% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.